-
Innovation Ranking
NewInnovation Ranking – Precigen Inc
Precigen Inc (Precigen), formerly Intrexon Corp, is a clinical stage biotechnology company that develops synthetic biology solutions. It offers clinical and pre clinical products. The company clinical products include PRGN-3006, PRGN-3005, AG019, PRGN-2009, PRGN-2012 and PRGN-3007. The company's pre clinical product portfolio comprises of PRGN-3008, PRGN-5001,PRGN-2010, PRGN-2011, PRGN-5002, PRGN-2013, AG017, PRGN-3009 and PRGN-3010. Precigen provides treatment in areas of immuno-oncology, autoimmune disorders, infectious diseases, solid tumors, celiac disease, heart failure, ovarian cancer and type 1 diabetes. It therapeutics platforms include...
-
Company Insights
Innovation and Patenting activity of Precigen Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Precigen Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3006 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3006 in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3006 in Myelodysplastic Syndrome Drug Details: PRGN-3006 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3006 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3006 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3006 in Refractory Acute Myeloid Leukemia Drug Details: PRGN-3006 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3006 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3006 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3006 in Relapsed Acute Myeloid Leukemia Drug Details: PRGN-3006 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3006 in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3006 in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3006 in Chronic Myelomonocytic Leukemia (CMML) Drug Details: PRGN-3006 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LGK-974 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LGK-974 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LGK-974 in Solid Tumor Drug Details: LGK-974 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LNS-8801 in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LNS-8801 in Malignant Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LNS-8801 in Malignant Mesothelioma Drug Details: LNS-8801 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LNS-8801 in Vaginal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LNS-8801 in Vaginal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LNS-8801 in Vaginal Cancer Drug Details: LNS-8801 is under development for the...